A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Tango Therapeutics was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We leverage our state-of-the-art target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. Tumor suppressor gene loss remains a largely unaddressed target space specifically because these genetic events cannot be directly targeted. Our novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse tumor suppressor gene mediated immune evasion which prevents the immune system from recognizing and killing cancer cells.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 67M | - | - | - | 37M | - |
| Net Income | -101M | -130M | -102M | -108M | -58M | -52M |
| EPS | $-0.91 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | $-1.63 |
| Free Cash Flow | -147M | -132M | -120M | -117M | -61M | 69M |
| ROIC | -1207.3% | -65.3% | -40.2% | -43.4% | -16.9% | -106.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.59 | 0.59 | 0.75 | 0.45 | 4.37 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -110M | -146M | -114M | -111M | -58M | -52M |
| Operating Margin | -165.9% | - | - | - | -157.1% | - |
| ROE | -62.8% | -57.6% | -40.2% | -43.4% | -16.9% | -134.6% |
| Shares Outstanding | 135M | 109M | 94M | 88M | 62M | 32M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | 37M | N/A | N/A | N/A | 67M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -52M | -58M | -111M | -114M | -146M | -110M |
| Op. Margin | N/A | -157.1% | N/A | N/A | N/A | -165.9% |
| Net Income | -52M | -58M | -108M | -102M | -130M | -101M |
| Net Margin | N/A | -157.2% | N/A | N/A | N/A | -151.1% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -106.8% | -16.9% | -43.4% | -40.2% | -65.3% | N/M |
| ROE | -134.6% | -16.9% | -43.4% | -40.2% | -57.6% | -62.8% |
| ROA | -25.1% | -11.6% | -24.8% | -25.3% | -36.2% | -47.8% |
| Cash Flow | ||||||
| Op. Cash Flow | 70M | -60M | -109M | -118M | -132M | -146M |
| Free Cash Flow | 69M | -61M | -117M | -120M | -132M | -147M |
| Owner Earnings | 68M | -68M | -125M | -139M | -163M | -177M |
| CapEx | 1.1M | 1.8M | 7.7M | 1.5M | 754K | 950K |
| Maint. CapEx | 718K | 897K | 1.6M | 2.4M | 2.5M | 2.5M |
| Growth CapEx | 388K | 940K | 6.1M | 0 | 0 | 0 |
| D&A | 718K | 897K | 1.6M | 2.4M | 2.5M | 2.5M |
| CapEx/OCF | 1.6% | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.8M | 7.8M | 14M | 19M | 29M | 29M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -153M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 153M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 4.37 | 0.45 | 0.75 | 0.59 | 0.59 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 39M | 345M | 249M | 253M | 200M | 160M |
| Total Assets | 207M | 500M | 436M | 403M | 316M | 210M |
| Total Liabilities | 169M | 155M | 187M | 149M | 117M | 13M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -103M | -161M | -270M | -371M | -502M | -502M |
| Working Capital | 153M | 452M | 320M | 301M | 228M | 228M |
| Current Assets | 194M | 492M | 375M | 347M | 266M | 266M |
| Current Liabilities | 41M | 41M | 56M | 46M | 38M | 38M |
| Per Share Data | ||||||
| EPS | -1.63 | -0.94 | -1.23 | -1.08 | -1.19 | -0.91 |
| Owner EPS | 2.12 | -1.10 | -1.42 | -1.48 | -1.49 | -1.32 |
| Book Value | 1.21 | 5.56 | 2.84 | 2.69 | 1.82 | 1.19 |
| Cash Flow/Share | 2.20 | -0.96 | -1.24 | -1.25 | -1.20 | -0.73 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 31.9M | 62.0M | 87.9M | 94.2M | 109.5M | 134.6M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -26.4 |
| P/FCF | 5.1 | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 9.1 | 1.9 | 2.5 | 3.9 | 1.7 | 20.2 |
| Price/Sales | N/A | 19.6 | N/A | N/A | N/A | 48.7 |
| FCF Yield | 19.6% | -9.4% | -18.4% | -12.3% | -38.7% | -4.5% |
| Market Cap | 352M | 650M | 633M | 975M | 342M | 3.2B |
| Avg. Price | 10.43 | 11.69 | 6.55 | 6.06 | 8.18 | 24.06 |
| Year-End Price | 11.03 | 10.49 | 7.20 | 10.35 | 3.12 | 24.06 |
Tango Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -26.9%.
Tango Therapeutics, Inc. (TNGX) has a 5-year average return on invested capital (ROIC) of -54.5%. This is below average and may indicate limited pricing power.
Tango Therapeutics, Inc. (TNGX) has a market capitalization of $3.2B. It is classified as a mid-cap stock.
Tango Therapeutics, Inc. (TNGX) does not currently pay a regular dividend.
Tango Therapeutics, Inc. (TNGX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Tango Therapeutics, Inc. (TNGX) generated $-132 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Tango Therapeutics, Inc. (TNGX) has a debt-to-equity ratio of 0.59. This indicates moderate leverage.
Tango Therapeutics, Inc. (TNGX) reported earnings per share (EPS) of $-1.19 in its most recent fiscal year.
Tango Therapeutics, Inc. (TNGX) has a return on equity (ROE) of -57.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for Tango Therapeutics, Inc. (TNGX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Tango Therapeutics, Inc. (TNGX) has a book value per share of $1.82, based on its most recent annual SEC filing.